Glenmark Pharma gets USFDA nod for cholesterol lowering drug

Epic Update Glenmark
Epic Update Glenmark

Glenmark Pharmaceuticals has received final approval from the US health regulator for Colesevelam Hydrochloride for oral suspension, used to lower cholesterol levels in the blood. The approval has been granted by the United States Food and Drug Administration (USFDA) in the strengths of 1.875 grams/packet and 3.75 grams/packet, the company said in a BSE filing today.

For Real Time News & Trading Trends Keep Liking Epic Research Limited

Facebook

Twitter

YouTube

Pinterest

Linkedin

Google+

Share Button

About the Author

Epic Research
Epic Research
Epic Research - Investment Adviser is a leading financial services provider with presence in Indian and other global capital markets. Call on - 0731-664-2300